Development of aztherapeutics T cell platform for Alzheimer's disease with car-t therapy

Today, AZTherapies announced the acquisition of Smith Therapeutics to acquire its proprietary regulatory T cell (Treg) engineering platform It is hoped that engineering Treg cells can inhibit neuroinflammation, treat neurodegenerative diseases including Alzheimer's disease, and enhance its research and development pipeline Founded in 2017, Smith's proprietary T cell engineering platform aims to reduce neuroinflammation and regulate cell health balance At present, the company has successfully developed car Treg therapy targeting brain glial cells with immunosuppressive function Previous studies have shown that Tregs can inhibit microglia activity and reduce neuroinflammation in neurodegenerative disease models, showing their potential in the treatment of progressive supranuclear paralysis (PSP), Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS) and other diseases Aztherapies has an innovative treatment for Alzheimer's disease in the phase 3 clinical stage Its mechanism includes reducing neuroinflammation and transforming microglia into a "neuroprotective" state According to the press release, Dr Philip Ashton rickardt, founder and CEO of Smith, will join the leadership team of aztherapies as the new senior vice president of immunology "Our common goal is to treat neurodegenerative diseases by inhibiting neuritis," said Dr Philip Ashton rickardt, founder and CEO of Smith Aztherapies' expertise in drug development and clinical trials will be able to advance car Treg technology and fundamentally change the progression of neurodegenerative diseases " reference material: [1] AZTherapies Strengthens Neuroinflammation-Targeted Pipeline Through Acquisition of Smith Therapeutics, Retrieved October 24, 2019, from https:// A kind of